<DOC>
	<DOCNO>NCT01268878</DOCNO>
	<brief_summary>The end study describe effect febrile neutropenia patient receive chemotherapy docetaxel+cisplatin+fluorouracil ( TPF ) .</brief_summary>
	<brief_title>Hematologic Toxicity Observation Docetaxel+ Cisplatin+ Fluorouracil ( TPF ) Medical Protocol</brief_title>
	<detailed_description>In study describe - habit medical staff prescription growth factor antibiotic prophylaxis - ratio patient treat growth factor primary secondary prophylaxis - ratio patient treat primary prophylaxis present febrile neutropenia - ratio patient need hospitalize duration hospitalization . - cause lateness , decreasing , stop chemotherapy - antibiotic growth factor prophylaxis tolerance .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>patient histologically prove head neck squamous cell carcinoma age : 18 patient begin chemotherapy ( docetaxel+cisplatin+ 5FU ) patient must inform automatic data process concerning . previous chemotherapy head neck squamous cell carcinoma previous chemotherapy cancer two year intercurrent illness could significantly interfere chemotherapy HIV infection , infection active febrile illness , chronic intestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>effect febrile neutropenia result chemotherapy TPF</keyword>
</DOC>